Compare Manhattan Associates Inc (MANH) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Zimmer Biomet Holdings Inc — how do they compare? Manhattan Associates Inc trades at $166.09 (market cap $9.79B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| MANH | ZBH | |
|---|---|---|
Market Cap | $9.79B | $17.36B |
Sector | Technology | Health |
52-Week High | $227.94 | $107.71 |
52-Week Low | $120.88 | $79.58 |
Enterprise Value | $9.62B | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $165.51, up 1.42% today, with a bullish technical outlook supported by moving averages and strong support at $162. The company demonstrates robust fundamentals with a 19.68% net margin and consistent earnings beats in recent quarters. Analyst sentiment remains positive with 73% buy ratings and a $192.80 consensus target, though an ongoing legal investigation has generated negative news flow.
MANH presents a growth opportunity with high profitability and earnings momentum, but faces near-term risks from legal scrutiny and premium valuations. The stock's technical strength and fundamental performance support upside potential, though investors should weigh the legal overhang against strong operational execution.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
